Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

TWITLIEDETECTOR Feb. 4 at 1:36 AM

$AEON notice the run to $1 then keeping it over $1.09. the game is changing and this is my last post on resistance. good luck to all of you.

0 · Reply

TWITLIEDETECTOR Feb. 3 at 4:17 PM

$AEON needs to break 1.23

1 · Reply

killer_7 Feb. 3 at 1:36 PM

$AEON 👀

0 · Reply

TWITLIEDETECTOR Feb. 3 at 1:49 AM

$AEON tight channel. resting at the bottom. seems bullish. i hope im not wrong

0 · Reply

BillionerOfKing Feb. 3 at 12:22 AM

$AEON Current Stock Price: $1.15

0 · Reply

HalEugene Feb. 2 at 8:06 PM

$AEON

0 · Reply

Mandi63 Feb. 2 at 7:52 PM

$AEON any day..

2 · Reply

Traidn Feb. 2 at 4:38 PM

$AEON 🚨

0 · Reply

TWITLIEDETECTOR Feb. 2 at 4:21 AM

$AEON algo AI is now 1.36 to 1.91k

0 · Reply

TWITLIEDETECTOR Feb. 1 at 7:15 PM

$AEON take a look at barchart opinion. then look at your other micro caps

0 · Reply

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Dec 19, 2025, 6:00 PM EST - 6 weeks ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Dec 15, 2025, 4:05 PM EST - 7 weeks ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Nov 20, 2025, 8:30 AM EST - 2 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Nov 14, 2025, 8:30 AM EST - 2 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 13, 2025, 8:30 AM EST - 2 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Oct 1, 2025, 8:00 AM EDT - 4 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 6 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:05 PM EDT - 9 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 9 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 25, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 21, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 1 year ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

TWITLIEDETECTOR Feb. 4 at 1:36 AM

$AEON notice the run to $1 then keeping it over $1.09. the game is changing and this is my last post on resistance. good luck to all of you.

0 · Reply

TWITLIEDETECTOR Feb. 3 at 4:17 PM

$AEON needs to break 1.23

1 · Reply

killer_7 Feb. 3 at 1:36 PM

$AEON 👀

0 · Reply

TWITLIEDETECTOR Feb. 3 at 1:49 AM

$AEON tight channel. resting at the bottom. seems bullish. i hope im not wrong

0 · Reply

BillionerOfKing Feb. 3 at 12:22 AM

$AEON Current Stock Price: $1.15

0 · Reply

HalEugene Feb. 2 at 8:06 PM

$AEON

0 · Reply

Mandi63 Feb. 2 at 7:52 PM

$AEON any day..

2 · Reply

Traidn Feb. 2 at 4:38 PM

$AEON 🚨

0 · Reply

TWITLIEDETECTOR Feb. 2 at 4:21 AM

$AEON algo AI is now 1.36 to 1.91k

0 · Reply

TWITLIEDETECTOR Feb. 1 at 7:15 PM

$AEON take a look at barchart opinion. then look at your other micro caps

0 · Reply

TWITLIEDETECTOR Jan. 31 at 5:16 PM

$AEON hopefully when this runs hold through 1.40 to 1.60. that may help break down 2. hopefully the big guys hold and carry us with them. again. all my posts are just my opinion. i could be WRONG. this is still the best near term bullish play i could find in micro cap

0 · Reply

TWITLIEDETECTOR Jan. 31 at 4:28 AM

$AEON if this stock runs which i hope it does there will be alot confusion on the move up. lots of fake outs.

1 · Reply

4by Jan. 30 at 10:30 PM

$AEON So this is around $0.014 pre 1:73 reverse split in Feb 2025?

2 · Reply

TWITLIEDETECTOR Jan. 30 at 9:39 PM

$AEON in my opinion this looks like this can hit $2 with good volume. getting by $2 looks real good. HOWEVER, this could always change and i could be wrong. i’m following a lot of other baby bios and they all suck right now but i do see some breakouts on the horizon. AEON im hoping to be rare like CAPR

0 · Reply

TWITLIEDETECTOR Jan. 30 at 6:45 PM

$AEON if it goes over 1.32. it could run to $2

0 · Reply

BryceyBoy Jan. 30 at 2:29 PM

$AEON We really need some good volume here

2 · Reply

Dfastpitchchic5 Jan. 30 at 2:18 PM

$AEON

0 · Reply

TWITLIEDETECTOR Jan. 30 at 3:44 AM

$AEON i’m talking to myself on here. i think the filings are bullish

2 · Reply

TWITLIEDETECTOR Jan. 30 at 3:30 AM

$AEON more filings posted

1 · Reply

TWITLIEDETECTOR Jan. 30 at 2:59 AM

$AEON they have stopped pumping. 1.09 is in the rear view mirror. the question is they have to get it over $2

0 · Reply

TWITLIEDETECTOR Jan. 29 at 9:01 PM

$AEON tried selling some stock on close. only got a partial fill. that’s a little scary

1 · Reply

TWITLIEDETECTOR Jan. 29 at 8:45 PM

$AEON no buying or selling.

0 · Reply

Market Cap	13.73M
Revenue (ttm)	0.00
Net Income (ttm)	42.01M
EPS (ttm)	N/A
PE Ratio	0.45
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	59,600
Avg Vol	214,496
Day's Range	N/A - N/A
Shares Out	11.84M
Stochastic %K	27%
Beta	0.72
Analysts	Strong Sell
Price Target	$6.10